LncRNA and application thereof as detection marker or prognosis recurrence marker for breast cancer combined with lung cancer
A technology for breast cancer and lung cancer, applied in the field of biomedicine, can solve problems such as not having biological functions, achieve the effect of large amount of information, improve clinical diagnosis and prognosis evaluation, and simple operation
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0045] Example 1 (screening of differentially expressed lncRNAs in breast cancer and lung cancer)
[0046] In order to fully disclose the gene biomarkers of the present invention, the process of obtaining the gene biomarkers of the present invention is described in detail below.
[0047] Firstly, the differentially expressed lncRNAs were screened through the combination of TCGA, lncRNAdb, lncRNAdisease and qRT-PCR.
[0048] (1) On the TCGA database website ( http: / / www.cbioportal.org / ), select the gene expression profile type mRNA Expression z-Scores (RNA Seq V2RSEM) for breast cancer and lung cancer tissues, sort the generated results, and select the genetic change rate (mutation, copy number change and RNA expression change) in the breast respectively The four lncRNAs PVT1, linc00467, SNHG6, linc0657 with high expression in lung cancer, the four with high expression changes in EXOC3-AS1, PVT1, linc00467, HCG18, respectively, as Figure 1A and Figure 1B . Differentially...
Embodiment 2
[0070] Example 2 (difference in the expression level of lncRNA between compound cancer and adjacent tissues)
[0071] In this experiment, qRT-PCR was carried out in breast cancer and adjacent tissues, lung cancer and adjacent tissues of 11 patients with compound cancer, and the experimental data were analyzed to obtain the relative change multiple of breast cancer tissue or lung cancer tissue and adjacent samples. Then SPSS statistical software was used to perform independent sample t-test on all samples to analyze the expression of the above-screened lncRNAs in the corresponding tissues of 11 patients with compound cancer. Analysis of experimental data shows that AFAP1-AS1, PVT1, and HYMAI are down-regulated in breast cancer tissues, and MALAT1, SNHG6, and UCA1 are up-regulated in breast cancer tissues. The expression trend of BDNF-AS, linc00467 and other genes is not obvious or basically no difference; the expressions of PVT1, HCG18, EXOC3-AS1, NEAT1 are up-regulated in the ...
Embodiment 3
[0075] Example 3 (screening and determination of lncRNA biomarkers in breast cancer combined with lung cancer)
[0076] In this study, lncRNAs differentially expressed in breast cancer and lung cancer tissues were screened out and verified. If the expression of candidate lncRNA is different from that of simple primary breast cancer and lung cancer, it can be initially used as a biomarker for breast cancer combined with lung cancer. In contrast, it was found that SNHG6, which was low expressed in simple primary breast cancer, was highly expressed in breast cancer compound cancer (RQ=2.2), and NEAT1, which was low expressed in simple primary lung cancer, was highly expressed in lung cancer compound cancer (see figure 2 ). A large number of studies have proved that the oncogene PVT1 is highly expressed in breast cancer and lung cancer tissues. The gene chip results of 2509 breast cancer patients in the TCGA database show that PVT1 presents a gene amplification trend in about 22...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com